OBJECTIVE: Androgen deficiency is common in HIV-infected women. We investigated the long-term effects of transdermal testosterone on body composition, bone mineral density, quality of life, and safety. DESIGN:Twenty-five HIV-infected women with free testosterone below the median (< or =3 pg/ml) of the female normal range were randomized to receive transdermal testosterone (300 microg twice weekly) or identical placebo over 18 months. RESULTS: Women demonstrated low androgen levels (1.3 +/- 0.1 pg/ml) with relatively low weight (22.8 +/- 0.6 kg/m) and low bone mineral density (-0.61 +/- 0.17 SD hip T score) at baseline. No statistically significant differences were seen between the groups at baseline. The discontinuation rate was 16% and did not differ between treatment groups (P = 0.24). Free testosterone by equilibrium dialysis increased over 18 months (7.9 +/- 1.8 vs. 0.3 +/- 0.4 pg/ml; P = 0.002, testosterone vs. placebo). Testosterone was well tolerated and did not affect lipids, liver, or safety indices. Lean mass (1.8 +/- 0.5 vs. 0.8 +/- 0.9 kg; P = 0.04) and BMI (1.6 +/- 0.4 vs. 0.8 +/- 0.6 kg/m; P = 0.03, testosterone vs. placebo) increased in response to testosterone, whereas fat mass remained unchanged. Testosterone increased bone mineral density at the hip (0.01 +/- 0.01 vs. -0.01 +/- 0.01 g/cm; P = 0.02) and trochanter (0.01 +/- 0.01 vs. -0.02 +/- 0.01 g/cm; P = 0.01, testosterone vs. placebo). Testosterone significantly improved depression indices (-6.8 +/- 2.2 vs. -1.9 +/- 3.1; P = 0.02) and problems affecting sexual function (-1.8 +/- 0.8 vs. 0.5 +/- 0.5; P = 0.01, testosterone vs. placebo). CONCLUSION:Long-term testosterone administration was well tolerated in HIV-infected women and resulted in significant improvements in body composition, bone mineral density, and quality of life indices. Further evaluation of the safety and efficacy of testosterone use among HIV-infected women is warranted.
RCT Entities:
OBJECTIVE:Androgen deficiency is common in HIV-infectedwomen. We investigated the long-term effects of transdermal testosterone on body composition, bone mineral density, quality of life, and safety. DESIGN: Twenty-five HIV-infectedwomen with free testosterone below the median (< or =3 pg/ml) of the female normal range were randomized to receive transdermal testosterone (300 microg twice weekly) or identical placebo over 18 months. RESULTS:Women demonstrated low androgen levels (1.3 +/- 0.1 pg/ml) with relatively low weight (22.8 +/- 0.6 kg/m) and low bone mineral density (-0.61 +/- 0.17 SD hip T score) at baseline. No statistically significant differences were seen between the groups at baseline. The discontinuation rate was 16% and did not differ between treatment groups (P = 0.24). Free testosterone by equilibrium dialysis increased over 18 months (7.9 +/- 1.8 vs. 0.3 +/- 0.4 pg/ml; P = 0.002, testosterone vs. placebo). Testosterone was well tolerated and did not affect lipids, liver, or safety indices. Lean mass (1.8 +/- 0.5 vs. 0.8 +/- 0.9 kg; P = 0.04) and BMI (1.6 +/- 0.4 vs. 0.8 +/- 0.6 kg/m; P = 0.03, testosterone vs. placebo) increased in response to testosterone, whereas fat mass remained unchanged. Testosterone increased bone mineral density at the hip (0.01 +/- 0.01 vs. -0.01 +/- 0.01 g/cm; P = 0.02) and trochanter (0.01 +/- 0.01 vs. -0.02 +/- 0.01 g/cm; P = 0.01, testosterone vs. placebo). Testosterone significantly improved depression indices (-6.8 +/- 2.2 vs. -1.9 +/- 3.1; P = 0.02) and problems affecting sexual function (-1.8 +/- 0.8 vs. 0.5 +/- 0.5; P = 0.01, testosterone vs. placebo). CONCLUSION: Long-term testosterone administration was well tolerated in HIV-infectedwomen and resulted in significant improvements in body composition, bone mineral density, and quality of life indices. Further evaluation of the safety and efficacy of testosterone use among HIV-infectedwomen is warranted.
Authors: S Grinspoon; C Corcoran; K Miller; B M Biller; H Askari; E Wang; J Hubbard; E J Anderson; N Basgoz; H M Heller; A Klibanski Journal: J Clin Endocrinol Metab Date: 1997-05 Impact factor: 5.958
Authors: K Miller; C Corcoran; C Armstrong; K Caramelli; E Anderson; D Cotton; N Basgoz; L Hirschhorn; R Tuomala; D Schoenfeld; C Daugherty; N Mazer; S Grinspoon Journal: J Clin Endocrinol Metab Date: 1998-08 Impact factor: 5.958
Authors: Susan R Davis; Michele Moreau; Robin Kroll; Céline Bouchard; Nick Panay; Margery Gass; Glenn D Braunstein; Angelica Linden Hirschberg; Cynthia Rodenberg; Simon Pack; Helga Koch; Alain Moufarege; John Studd Journal: N Engl J Med Date: 2008-11-06 Impact factor: 91.245
Authors: Karen K Miller; Beverly M K Biller; Joan Hier; Elizabeth Arena; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2002-06 Impact factor: 5.958
Authors: L G Raisz; B Wiita; A Artis; A Bowen; S Schwartz; M Trahiotis; K Shoukri; J Smith Journal: J Clin Endocrinol Metab Date: 1996-01 Impact factor: 5.958
Authors: S Grinspoon; C Corcoran; H Askari; D Schoenfeld; L Wolf; B Burrows; M Walsh; D Hayden; K Parlman; E Anderson; N Basgoz; A Klibanski Journal: Ann Intern Med Date: 1998-07-01 Impact factor: 25.391
Authors: Dean J Wantland; Joseph P Mullan; William L Holzemer; Carmen J Portillo; Suzanne Bakken; Eva M McGhee Journal: J Pain Symptom Manage Date: 2011-01-13 Impact factor: 3.612
Authors: Ellen T M Laan; Jan M Prins; Rik H W van Lunsen; Pythia T Nieuwkerk; Marian A F Nievaard-Boon Journal: Sex Med Date: 2018-12-03 Impact factor: 2.491